Madrigal Pharmaceuticals’ Earnings ESP Falls –852%, Q4 Sales Seen at $313M
Madrigal Pharmaceuticals’ consensus estimate for Q4 sales stands at $313 million with EPS projected at $0.04, ahead of its February 19 release date. The company’s Earnings ESP plunged to –852.37% and its lone marketed therapy Rezdiffra drives 100% of revenues following four consecutive quarters of earnings misses.
1. Upcoming Q4 Results
Madrigal Pharmaceuticals will report fourth-quarter and full-year 2025 results on February 19, with analysts expecting $313 million in sales and $0.04 in EPS.
2. Historical Earnings Performance
The company has missed earnings estimates in three of the last four quarters, posting an average negative surprise of 17.17% and a 156.57% miss in the most recent quarter.
3. Earnings ESP and Analyst Rank
Madrigal’s Earnings ESP stands at –852.37%, reflecting negligible upside, coupled with a #4 analyst rank, indicating a limited probability of an earnings beat.
4. Product Concentration and Risks
Madrigal generates all revenues from Rezdiffra, its sole marketed therapy for MASH, exposing the company to single-product risk as it awaits broader adoption and potential label expansions.